Immix Biopharma Trial Results Selected for Oral Presentation at ASH
Interim NEXICART-2 results for NXC-201 are scheduled for oral presentation on Dec. 14, 2026, at 11:15 a.m. CDT.
Related stories
Ronesans Gayrimenkul Q3 Revenue Rises to 4.8 Billion Lira
Q3 revenue was 4.8 billion lira, compared with 4.0 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
Ronesans Gayrimenkul Yatirim Reports Q3 Net Profit of 5.3 Billion Lira
Net profit was 5.3 billion lira, compared with 11.6 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
Google invertirá USD 15.000 millones en Malasia
La inversión prevista contempla centros de datos, energía y agua.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
General Motors shares hit record high, up 4%
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
SolarEdge Reports Q3 Revenue of $326.1 Million, Adjusted EPS of $0.29
Third-quarter revenue was $326.1 million, in line with the midpoint of prior guidance. Adjusted EPS was $0.29 versus FactSet consensus of $0.04. SolarEdge forecast fourth-quarter r
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Kempower Reports Q3 Revenue Decline and Lowers 2026 Guidance
Kempower reported a 10% revenue decline and negative operative EBIT in Q3 2026, citing weakening charging investment. It lowered full-year 2026 guidance, while reporting a €128 mil
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC